Review of the epidemiology and burden of ulcerative colitis in Latin America.

abstract：BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...

journal_title：Therapeutic advances in gastroenterology

authors： Malespin M,Benyashvili T,Uprichard SL,Perelson AS,Dahari H,Cotler SJ

更新日期：2017-01-01 00:00:00

abstract：:Pancreatic neuroendocrine tumors (pNETs) are relatively rare malignancies. With secretory tumors such as insulinomas, vasoactive intestinal peptideomas, and gastrinomas, the hormone produced causes the symptom complex (e.g. hypoglycemia, peptic ulcer disease). With nonsecretory NETs, the clinical condition is determin...

journal_title：Therapeutic advances in gastroenterology

authors： Vinik AI,Raymond E

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Patients with Barrett's esophagus (BE) are commonly treated with proton-pump inhibitors (PPIs) to minimize the exposure of esophageal mucosa to stomach acid. However, the use of these medications can lead to significant hypergastrinemia in a subset of patients, which is concerning due to the known tumorigeni...

journal_title：Therapeutic advances in gastroenterology

authors： Green DA,Mlynarczyk CM,Vaccaro BJ,Capiak KM,Quante M,Lightdale CJ,Abrams JA

更新日期：2011-03-01 00:00:00

abstract：:Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...

journal_title：Therapeutic advances in gastroenterology

authors： Lam BP,Jeffers T,Younoszai Z,Fazel Y,Younossi ZM

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...

journal_title：Therapeutic advances in gastroenterology

authors： Bhat YM,Furth EE,Brensinger CM,Ginsberg GG

更新日期：2009-11-01 00:00:00

abstract：:Rates of transmission of hepatitis B virus (HBV) infection from organ donors with HBV markers to recipients along with reactivation of HBV during immunosuppression following transplantation have fallen significantly with the advent of hepatitis B immune globulin (HBIg) and effective antiviral therapy. Although the ava...

journal_title：Therapeutic advances in gastroenterology

authors： John S,Andersson KL,Kotton CN,Hertl M,Markmann JF,Cosimi AB,Chung RT

更新日期：2013-07-01 00:00:00

abstract：:Faecal incontinence, defined as the involuntary loss of solid or liquid stool, is a common problem affecting 0.8-8.3% of the adult population. Individuals suffering from faecal incontinence often live a restricted life with reduced quality of life. The present paper is a clinically oriented review of the pathophysiolo...

journal_title：Therapeutic advances in gastroenterology

authors： Duelund-Jakobsen J,Worsoe J,Lundby L,Christensen P,Krogh K

更新日期：2016-01-01 00:00:00

abstract：:Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...

journal_title：Therapeutic advances in gastroenterology

authors： Liu X,Yang Z,Latchoumanin O,Qiao L

更新日期：2016-11-01 00:00:00

abstract：:Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...

journal_title：Therapeutic advances in gastroenterology

authors： Kelesidis T,Pothoulakis C

更新日期：2012-03-01 00:00:00

abstract：:Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract cancer (BTC). Recent largescale molecular profiling studies have not only highlighted genomic differences characterizing tumors of the intrahe...

journal_title：Therapeutic advances in gastroenterology

authors： Lee H,Ross JS

更新日期：2017-06-01 00:00:00

abstract：:On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...

journal_title：Therapeutic advances in gastroenterology

authors： Bove V,Schepis T,Boškoski I,Landi R,Orlandini B,Pontecorvi V,Familiari P,Tringali A,Perri V,Costamagna G

更新日期：2020-06-24 00:00:00

abstract：:Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...

journal_title：Therapeutic advances in gastroenterology

authors： Zhou C,Adler DC,Becker L,Chen Y,Tsai TH,Figueiredo M,Schmitt JM,Fujimoto JG,Mashimo H

更新日期：2009-01-01 00:00:00

abstract：Background:Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-tr...

journal_title：Therapeutic advances in gastroenterology

authors： Kotze PG,Ma C,Mckenna N,Almutairdi A,Kaplan GG,Raffals LE,Loftus EV Jr,Panaccione R,Lightner AL

更新日期：2018-06-21 00:00:00

abstract：Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...

journal_title：Therapeutic advances in gastroenterology

authors： Mori H,Suzuki H,Omata F,Masaoka T,Asaoka D,Kawakami K,Mizuno S,Kurihara N,Nagahara A,Sakaki N,Ito M,Kawamura Y,Suzuki M,Shimada Y,Sasaki H,Matsuhisa T,Torii A,Nishizawa T,Mine T,Ohkusa T,Kawai T,Tokunaga K,Tak

更新日期：2019-07-04 00:00:00

abstract：Aims:Gastric cancer (GC) is the third leading cause of cancer death worldwide, but the burden of disease is not distributed evenly. GC screening routinely occurs in some high-incidence regions/countries and is generally cost-effective, which is attributed largely to the associated GC mortality reduction. In regions of ...

journal_title：Therapeutic advances in gastroenterology

authors： Canakis A,Pani E,Saumoy M,Shah SC

更新日期：2020-07-16 00:00:00

abstract：:Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...

journal_title：Therapeutic advances in gastroenterology

authors： Kopylov U,Seidman E

更新日期：2016-07-01 00:00:00

abstract：Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...

journal_title：Therapeutic advances in gastroenterology

authors： Kono Y,Kawano S,Okamoto Y,Obayashi Y,Baba Y,Sakae H,Abe M,Gotoda T,Inokuchi T,Kanzaki H,Iwamuro M,Kawahara Y,Okada H

更新日期：2018-01-14 00:00:00

abstract：Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...

journal_title：Therapeutic advances in gastroenterology

authors： Ozawa T,Ishihara S,Fujishiro M,Kumagai Y,Shichijo S,Tada T

更新日期：2020-03-20 00:00:00

abstract：:The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...

journal_title：Therapeutic advances in gastroenterology

authors： Oke S,Martin A

更新日期：2017-05-01 00:00:00

abstract：:In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...

journal_title：Therapeutic advances in gastroenterology

authors： Schreiber S

更新日期：2011-11-01 00:00:00

abstract：:Gut microbiota is a compilation of microorganisms dwelling in the entire mammalian gastrointestinal tract. They display a symbiotic relationship with the host contributing to its intestinal health and disease. Even a slight fluctuation in this equipoise may be deleterious to the host, leading to many pathological cond...

journal_title：Therapeutic advances in gastroenterology

authors： Bien J,Palagani V,Bozko P

更新日期：2013-01-01 00:00:00

abstract：Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...

journal_title：Therapeutic advances in gastroenterology

authors： Glover B,Patel N,Ashrafian H,Teare J

更新日期：2018-12-06 00:00:00

abstract：:Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...

journal_title：Therapeutic advances in gastroenterology

authors： Kim HY,Park JW

更新日期：2017-10-01 00:00:00

abstract：Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...

journal_title：Therapeutic advances in gastroenterology

authors： van Rossen TM,van Dijk LJ,Heymans MW,Dekkers OM,Vandenbroucke-Grauls CMJE,van Beurden YH

更新日期：2021-01-09 00:00:00

abstract：:In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...

journal_title：Therapeutic advances in gastroenterology

authors： Klenske E,Bojarski C,Waldner M,Rath T,Neurath MF,Atreya R

更新日期：2019-06-14 00:00:00

abstract：:Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...

journal_title：Therapeutic advances in gastroenterology

authors： Vilaseca M,Guixé-Muntet S,Fernández-Iglesias A,Gracia-Sancho J

更新日期：2018-11-25 00:00:00

abstract：Background:In patients with a large, unresectable hepatocellular carcinoma (HCC), the primary recommendation is for transarterial chemoembolization (TACE) but used alone TACE is not typically curative. Combinations of TACE followed in a delayed fashion by single-applicator thermal ablation have also been suboptimal. As...

journal_title：Therapeutic advances in gastroenterology

authors： Zhang TQ,Huang ZM,Shen JX,Chen GQ,Shen LJ,Ai F,Gu YK,Yao W,Zhang YY,Guo RP,Chen MS,Huang JH

更新日期：2019-08-21 00:00:00

abstract：Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...

journal_title：Therapeutic advances in gastroenterology

authors： Dehlholm-Lambertsen E,Hall BK,Jørgensen SMD,Jørgensen CW,Jensen ME,Larsen S,Jensen JS,Ehlers L,Dahlerup JF,Hvas CL

更新日期：2019-04-10 00:00:00

abstract：Background:Recent evidence has shown that the complete blood count (CBC) is abnormal in patients with Crohn's disease (CD). We aimed to investigate an effective CBC parameter and explore its impact on disease activity in a large CD cohort. Methods:We performed a retrospective analysis of patients with established CD w...

journal_title：Therapeutic advances in gastroenterology

authors： Chen R,Li L,Chao K,Hong M,Cao Q,Ye L,Zhou G,Fang X,Guo H,Cao X,Ye X,Zeng Z,Chen M,Zhang S

更新日期：2020-12-21 00:00:00

abstract：BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosph...

journal_title：Therapeutic advances in gastroenterology

authors： Ammendola M,Sacco R,Vescio G,Zuccalà V,Luposella M,Patruno R,Zizzo N,Gadaleta C,Marech I,Ruggieri R,Kocak IF,Ozgurtas T,Gadaleta CD,Sammarco G,Ranieri G

更新日期：2017-04-01 00:00:00